Höskuldsdóttir, Gudrún
Engström, My
Rawshani, Araz
Wallenius, Ville
Lenér, Frida
Fändriks, Lars
Mossberg, Karin
Eliasson, Björn
Funding for this research was provided by:
University of Gothenburg
Article History
Received: 10 February 2021
Accepted: 18 August 2021
First Online: 10 September 2021
Declarations
:
: The Ethical Regional Board of Gothenburg, approved the protocol (application 673–14). The ethics committee belongs to the Swedish Ethical Review Authority at the Government Offices of Sweden. Informed consent to participate was obtained from all study participants. All methods were carried out in accordance with relevant guidelines and regulations.Study nurse obtained written and verbal informed consent from study participants.
: Does not apply.
: Professor Eliasson reports personal fees (expert panels, lectures) from Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Mundipharma, Navamedic, NovoNordisk, RLS Global, and grants and personal fees from Sanofi, all outside the submitted work. He was also supported by Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse. Other authors report no competing interests.